Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Evotec and BI team up on Alzheimer’s
April 2007
SHARING OPTIONS:

HAMBURG, Germany—Evotec AG announced in March a multi-year collaboration with Boehringer Ingelheim to jointly identify novel targets for the treatment of Alzheimer's disease. The collaboration will also involve the Research Institute of Molecular Pathology in Vienna (IMP).
 
Based on the work using Evotec-IMP disease models, Boehringer Ingelheim will select and further validate target candidates for its in-house drug discovery program with the goal of developing innovative novel therapeutics. Financial details of this collaboration were not disclosed.
 
The contract also includes an option for Evotec to support Boehringer Ingelheim in the target validation process. If Boehringer Ingelheim exercises this option, Evotec is eligible for milestone payments of up to EUR 20 million plus royalties.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.